



Millennium Pharmaceuticals ([MLNM-news](#)) announced the initiation of a phase I/II, open-label, multicenter study of **MLN518** in combination with standard induction chemotherapy in patients with newly diagnosed **acute myelogenous leukemia** (AML). The trial will also assess MLN518 as a single-agent in remission maintenance therapy. This study, part of the Company's broad oncology development program, will evaluate the safety, tolerability and initial response rates of MLN518 in combination with cytarabine and daunorubicin, the standard induction chemotherapy in front-line AML.

Prohost Comments : Previous results from a single-agent phase I/II study of MLN518, presented at the annual meeting of the American Society of Hematology 2004, established a well-tolerated dose along with strong preliminary antileukemic activity.

A new milestone – good news

Read News [Millennium Initiates Combination Phase I/II Trial of MLN518 in Acute Myelogenous Leukemia](#)

PROHOST RESEARCH
P.O.BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>